genetics

Health Tech By Erin Brodwin and Katie Palmer

5 burning questions on the business of big genetics based on 23andMe’s filing to go public

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: 23andMe is going public, vaccine data abound, and Merck’s CEO is retiring

Health Tech By Matthew Herper

The Pajama Interview: A conversation with Anne Wojcicki and Richard Branson

Health Tech By Casey Ross and Matthew Herper

23andMe to go public via Richard Branson’s SPAC

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: JPM21: Déjà vu in Alzheimer’s research, debatable valuations in biotech, and OWS’s legacy

First Opinion By Chris Bakerlee

Mother Nature is not ‘the ultimate bioterrorist’

Health By Elizabeth Cooney

FDA approves genetically altering pigs, to potentially make food, drugs, and transplants safer

In the Lab By Eric Boodman

Genetic reprogramming rejuvenates nerve cells and restores vision in mice

Health By Nicholas St. Fleur

Leading genetics experts call for more racial representation in their industry

Biotech By Meghana Keshavan

Gene therapy pioneer develops a new approach to curb the side effects of treatment

Health Tech By Casey Ross

A boy’s passing came too soon, but not before his life led to crucial medical discoveries

In the Lab By Andrew Joseph

The CRISPR story: How a basic research discovery changed science and led to a Nobel

In the Lab By Sharon Begley

Dust off the crystal ball: It’s time for STAT’s 2020 Nobel Prize predictions

Health By Kate Sheridan

Early research from 23andMe strengthens link between blood types and Covid-19

First Opinion By Josh Quick

Real-time gene sequencing can help control — and may someday prevent — pandemics

Pharma By Kate Sheridan

23andMe’s next challenge: ensuring its customers can get drugs developed with their data

First Opinion By Josephine Johnston

The U.S. must do some heavy lifting to prepare for heritable genome editing

Health By Andrew Joseph

Expert panel lays out guidelines for germline editing, while warning against pursuit of ‘CRISPR babies’

First Opinion By Wolfram Nothaft, Gregory Moore, and Yann Le Cam

Using telehealth to revolutionize the speed of making rare disease diagnoses

Health Tech By Rebecca Robbins

STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic

Biotech By Elizabeth Cooney

Wary hemophilia patients say they’re willing to wait longer for a safe gene therapy

In the Lab By Rebecca Robbins

Genomic sequencing to screen newborns raises more false alarms than routine blood tests, study finds

Health Tech By Erin Brodwin

Blackstone agrees to buy Ancestry in $4.7 billion deal

Pharma By Matthew Herper

Cancer drug is the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration

In the Lab By Sharon Begley

Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases